In the early phase of infection (11–20 dpso), IgG and IgA antibodies against S1 of SARS‐CoV‐2 were detected in 70.4% and 88.9% of the samples (n = 29), respectively, while IgG and IgM antibodies against NCP were detected in 86.2% and 50%, respectively. The gene discussed is CD79A; the disease is infection.